Intrahepatic Cholangiocarcinoma: Rising Burden and Glaring Disparities

Ujwal Yanala,Gautam Malhotra,Chandrakanth Are,James Padussis
DOI: https://doi.org/10.1245/s10434-019-07176-3
IF: 4.339
2019-02-28
Annals of Surgical Oncology
Abstract:Cholangiocarcinoma is the second most common primary hepatic malignancy worldwide, next to hepatocellular carcinoma. In the US alone, cholangiocarcinoma accounts for approximately 5000 new cases every year. Of the different types of cholangiocarcinoma (extrahepatic, intrahepatic, and hilar), intrahepatic cholangiocarcinoma (ICC) is the least common but accounts for high mortality. In the last two to three decades, ICC has become the leading cause of primary hepatic malignancy-related deaths in England and Wales.<span><a href="#CR1">1</a></span> Although ICC is more common in East Asian countries such as China and Thailand, it has been reported that the incidence and mortality of ICC have been increasing in developed Western countries, including the US and the UK.<span><a href="#CR1">1</a></span> Studies with data gathered from the Surveillance, Epidemiology, and End Results (SEER) program database have shown some interesting findings with respect to changes in the incidence and mortality based on ethnic and racial variations in the US. One study based on SEER data from the years 1990 to 2001 showed that the age-adjusted prevalence in Hispanics was 1.22/100,000 (highest) and 0.3/100,000 in African Americans (lowest). American Indian/Alaska Natives and Asian/Pacific Islanders were noted to have higher mortality rates compared with other groups.<span><a href="#CR2">2</a></span> The same research group, in their most recent epidemiological study based on the SEER database from 1995 to 2014, found that the incidence has increased significantly. The incidence rate increased threefold from 0.49/100,000 in 1995 to 1.49/100,000 in 2014, with an average annual rate of increase of 5.49%. The incidence rate was higher among males versus females (0.97 vs. 0.88 per 100,000) and among Hispanics versus non-Hispanics (1.8 vs. 0.89 per 100,000). Hispanics had poorer 5-year all-cause and ICC-specific mortality (hazard ratio [HR] 1.11, 95% confidence interval [CI] 1.05–1.19; HR 1.15, 95% CI 1.07–1.24, respectively). This study also found that while African Americans had a lower incidence, they had shorter survival compared with Caucasians, likely due to the presentation at late stages. Asian/Pacific Islanders had a higher ICC incidence rate than any other racial group in the US.<span><a href="#CR3">3</a></span> Survival rates were also poor for individuals over the age of 45 years, men, African Americans, and American Indians/Alaska Natives who are more prone to be uninsured.<span><a href="#CR3">3</a></span> In summary, this study demonstrated substantial ethnic-, racial-, sex-, and age-related variations in ICC incidence and survival.
oncology,surgery
What problem does this paper attempt to address?